These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 34579874)

  • 1. Solid-solution fibrous dosage forms for immediate delivery of sparingly-soluble drugs: Part 2. 3D-micro-patterned dosage forms.
    Blaesi AH; Saka N
    Mater Sci Eng C Mater Biol Appl; 2021 Oct; 129():110211. PubMed ID: 34579874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Solid-solution fibrous dosage forms for immediate delivery of sparingly-soluble drugs: Part 1. Single fibers.
    Blaesi AH; Saka N
    Mater Sci Eng C Mater Biol Appl; 2020 Apr; 109():109918. PubMed ID: 32228997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of excipient molecular weight in drug release by fibrous dosage forms with close packing and high drug loading.
    Blaesi AH; Saka N
    Int J Pharm; 2021 Sep; 606():120009. PubMed ID: 33246051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expandable, dual-excipient fibrous dosage forms for prolonged delivery of sparingly-soluble drugs.
    Blaesi AH; Saka N
    Int J Pharm; 2022 Mar; 615():120396. PubMed ID: 33716100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expandable fibrous dosage forms for prolonged drug delivery.
    Blaesi AH; Saka N
    Mater Sci Eng C Mater Biol Appl; 2021 Jan; 120():110144. PubMed ID: 33545806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastroretentive fibrous dosage forms for prolonged delivery of sparingly-soluble tyrosine kinase inhibitors. Part 1: Dosage form design, and models of expansion, post-expansion mechanical strength, and drug release.
    Blaesi AH; Saka N
    Int J Pharm; 2024 Jun; ():124360. PubMed ID: 38909925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Towards functional characterization of excipients for oral solid dosage forms using UV-vis imaging. Liberation, release and dissolution.
    Li Z; Sun Y; Bar-Shalom D; Mu H; Larsen SW; Jensen H; Østergaard J
    J Pharm Biomed Anal; 2021 Feb; 194():113789. PubMed ID: 33298380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 3D-micro-patterned fibrous dosage forms for immediate drug release.
    Blaesi AH; Saka N
    Mater Sci Eng C Mater Biol Appl; 2018 Mar; 84():218-229. PubMed ID: 29519432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrous dosage forms by wet 3D-micro-patterning: Process design, manufacture, and drug release rate.
    Blaesi AH; Saka N
    Eur J Pharm Biopharm; 2018 Sep; 130():345-358. PubMed ID: 29932976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microstructural effects in drug release by solid and cellular polymeric dosage forms: A comparative study.
    Blaesi AH; Saka N
    Mater Sci Eng C Mater Biol Appl; 2017 Nov; 80():715-727. PubMed ID: 28866221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A New Extrudable Form of Hypromellose: AFFINISOL™ HPMC HME.
    Huang S; O'Donnell KP; Keen JM; Rickard MA; McGinity JW; Williams RO
    AAPS PharmSciTech; 2016 Feb; 17(1):106-19. PubMed ID: 26335416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypromellose - A traditional pharmaceutical excipient with modern applications in oral and oromucosal drug delivery.
    Mašková E; Kubová K; Raimi-Abraham BT; Vllasaliu D; Vohlídalová E; Turánek J; Mašek J
    J Control Release; 2020 Aug; 324():695-727. PubMed ID: 32479845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanical strength and gastric residence time of expandable fibrous dosage forms.
    Blaesi AH; Kümmerlen D; Richter H; Saka N
    Int J Pharm; 2022 Feb; 613():120792. PubMed ID: 34363914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium Lauryl Sulfate Competitively Interacts with HPMC-AS and Consequently Reduces Oral Bioavailability of Posaconazole/HPMC-AS Amorphous Solid Dispersion.
    Chen Y; Wang S; Wang S; Liu C; Su C; Hageman M; Hussain M; Haskell R; Stefanski K; Qian F
    Mol Pharm; 2016 Aug; 13(8):2787-95. PubMed ID: 27337060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Solid State NMR Investigation for Molecular States of Specialized Formulation to Improve the Water Solubility of Poorly Water-soluble Drugs].
    Higashi K
    Yakugaku Zasshi; 2021; 141(9):1063-1069. PubMed ID: 34471007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biopharmaceutical Understanding of Excipient Variability on Drug Apparent Solubility Based on Drug Physicochemical Properties: Case Study-Hypromellose (HPMC).
    Zarmpi P; Flanagan T; Meehan E; Mann J; Fotaki N
    AAPS J; 2020 Feb; 22(2):49. PubMed ID: 32072317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biopharmaceutical implications of excipient variability on drug dissolution from immediate release products.
    Zarmpi P; Flanagan T; Meehan E; Mann J; Østergaard J; Fotaki N
    Eur J Pharm Biopharm; 2020 Sep; 154():195-209. PubMed ID: 32681966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastroretentive fibrous dosage forms for prolonged delivery of sparingly-soluble tyrosine kinase inhibitors. Part 2: Experimental validation of the models of expansion, post-expansion mechanical strength, and drug release.
    Blaesi AH; Saka N
    Int J Pharm; 2024 Jun; ():124361. PubMed ID: 38909924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developing dissolution testing methodologies for extended-release oral dosage forms with supersaturating properties. Case example: Solid dispersion matrix of indomethacin.
    Tajiri T; Morita S; Sakamoto R; Mimura H; Ozaki Y; Reppas C; Kitamura S
    Int J Pharm; 2015 Jul; 490(1-2):368-74. PubMed ID: 26022889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On the exfoliating polymeric cellular dosage forms for immediate drug release.
    Blaesi AH; Saka N
    Eur J Pharm Biopharm; 2016 Jun; 103():210-218. PubMed ID: 27045468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.